

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



PCT

(43) International Publication Date
9 June 2005 (09.06.2005)

(10) International Publication Number
WO 2005/051324 A2

(51) International Patent Classification⁷: A61K

(21) International Application Number:
PCT/US2004/039673

(22) International Filing Date:
24 November 2004 (24.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/524,961 25 November 2003 (25.11.2003) US
60/580,139 16 June 2004 (16.06.2004) US
60/581,293 18 June 2004 (18.06.2004) US

(71) Applicant (for all designated States except US): 3M
INNOVATIVE PROPERTIES COMPANY [US/US];
3M Center, Post Office Box 33427, Saint Paul, Minnesota
55133-3427 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KREPSKI, Larry
R., [US/US]; Post Office Box 33427, Saint Paul, Min-
nesota 55133-3427 (US). DELLARIA, Joseph F., Jr.,
[US/US]; Post Office Box 33427, Saint Paul, Minnesota
55133-3427 (US). DUFFY, Daniel E., [US/US]; Post Of-
fice Box 33427, Saint Paul, Minnesota 55133-3427 (US).
AMOS, David T., [US/US]; Post Office Box 33427, Saint
Paul, Minnesota 55133-3427 (US). ZIMMERMANN,
Bernhard M., [CH/US]; Post Office Box 33427, Saint
Paul, Minnesota 55133-3427 (US). SQUIRE, David J.,
[US/US]; Post Office Box 33427, Saint Paul, Minnesota
55133-3427 (US). MARSZALEK, Gregory J., [US/US];
Post Office Box 33427, Saint Paul, Minnesota 55133-3427
(US). HEPPNER, Philip D., [US/US]; Post Office Box
33427, Saint Paul, Minnesota 55133-3427 (US). KSHIR-
SAGAR, Tushar A., [IN/US]; Post Office Box 33427,
Saint Paul, Minnesota 55133-3427 (US).

(74) Agents: ERSFELD, Dean A., et al.; Office of Intellectual
Property Counsel, Post Office Box 33427, Saint Paul, Min-
nesota 55133-3427 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI
patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations

Published:

- without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMI-
DAZONAPHTHYRIDINES

(57) Abstract: Imidazo-quinoline, -pyridine, and -naphthyridine ring systems substituted at the 1-position, pharmaceutical com-
positions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing
cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

WO 2005/051324 A2